<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Skin substitutes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Skin substitutes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Skin substitutes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shahriar Shahrokhi, MD, FRCSC, FACS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc G Jeschke, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1056738425"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Skin substitutes are a heterogeneous group of biologic, synthetic, or biosynthetic materials that can provide temporary or permanent coverage of open skin wounds. The aim of skin substitutes is to replicate the properties of the normal skin. Skin substitutes are an important adjunct in the management of acute or chronic wounds and can be used to cover defects following burns or other injuries, or for reconstruction, such as for release of extensive severe post-burn contractures [<a href="#rid1">1</a>]. </p><p>Each skin substitute has its own unique set of advantages and disadvantages. Since wound healing tends to be unique to the individual, the use of skin substitutes is highly personalized with the choice of skin substitute depending upon the type of wound (ie, acute, chronic), its etiology (eg, trauma, chronic inflammation), and the skin component (ie, epidermis, dermis, or both) that requires replacement. In addition, the desired functional and aesthetic outcomes need to be considered. Other factors that determine the choice of skin substitute depend on whether wound coverage is temporary or permanent. </p><p>The types of skin substitutes, indications for use, general properties, and tips for application are reviewed here. Skin autografting is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/15118.html" rel="external">"Skin autografting"</a>.)</p><p class="headingAnchor" id="H1759629945"><span class="h1">AVAILABLE PRODUCTS</span><span class="headingEndMark"> — </span>Skin substitutes are a heterogeneous group of biologic, synthetic, or biosynthetic materials that can provide temporary or permanent coverage of open skin wounds. Skin substitutes ideally possess the composition and function of skin or have the potential for autologous regenerative healing when applied to a wound [<a href="#rid2">2</a>]. When skin substitutes are applied in an optimized setting, they can provide a unique solution for difficult-to-treat wounds. Significant progress has been made in the past several decades in the production and engineering of these materials. </p><p>Prior to using a specific skin substitute, it is essential that the clinician has full understanding of the material being used and its properties. Each wound has a unique and variable microenvironment, and many products have been developed to try to accommodate the various needs. As an example, skin substitutes that contain a dermal component have added pliability [<a href="#rid3">3-6</a>]. Some of the available products and their efficacy are provided below and summarized in the table  (<a class="graphic graphic_table graphicRef118083" href="/d/graphic/118083.html" rel="external">table 1</a>) [<a href="#rid7">7</a>]. A comprehensive listing of skin substitutes available for use in the United States and their properties can be found in the Agency for Healthcare Research and Quality (AHRQ) document [<a href="#rid8">8</a>]. </p><p>Most commonly, human skin allografts, amnionic membrane products, and xenografts derived from a variety of animals (eg, pig, frog, fish) are used in specialized burn centers [<a href="#rid8">8</a>]. The earliest description of the use of xenograft as a form of skin substitute was from the 15<sup>th</sup> century BC. Since then, a variety of skin substitutes have been developed. Skin allografts have proven to be effective in preventing insensible fluid, electrolytes, and protein loss and also act as a barrier to microbial contamination/infection. Allografts have also become indispensable in patients with large total body surface area burns with inadequate donor site availability. (See  <a class="medical medical_review" href="/d/html/114178.html" rel="external">"Treatment of deep burns", section on 'Managing large burn wounds'</a>.)</p><p>However, tissue engineering has significantly advanced the development of skin substitutes beyond allografts. There has been much focus on materials that can deliver all the cells and factors required for tissue healing. In the future, the focus will likely include incorporation of stem cells into scaffolds, as well as three-dimensional printing technology. </p><p>The general characteristics required when engineering functional skin substitutes include the ability to [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Protect the integument from loss of fluid and prevent infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provide a stable, biodegradable scaffold that promotes the synthesis of new dermal tissue</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allow the host or other cells to proliferate within the scaffold as functional dermal cells, rather than as scar tissue</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resist shearing forces, while still being easy to handle</p><p></p><p class="headingAnchor" id="H3461591918"><span class="h1">TERMINOLOGY AND CLASSIFICATION</span><span class="headingEndMark"> — </span>There is no universally accepted classification system that allows for simple categorization of all the products that are commercially available. A technology assessment report from the Agency for Healthcare Research and Quality (AHRQ) from January 2019 listed 74 products classified as skin substitutes [<a href="#rid8">8</a>]. Regardless of the classification system used, the clinician needs to have an understanding of the materials used and their ultimate purpose. In the author's opinion, it is ideal to have knowledge of at least one product per category to enhance the ability to treat a variety of wounds.</p><p class="headingAnchor" id="H2465614630"><span class="h2">Kumar classification</span><span class="headingEndMark"> — </span>The most commonly used system proposes three classes  (<a class="graphic graphic_table graphicRef118082" href="/d/graphic/118082.html" rel="external">table 2</a>) [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Class I – Temporary, impervious dressing material</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mechanical traits of epidermis but no cells</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subcategorized as single layer or bilayer</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class II – Single-layer durable skin substitutes</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Epidermal substitutes – Functionally similar to the epidermis </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dermal substitute – Including collagen sheets, dermal matrices, and porcine collagen sheets </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class III – Composite skin substitutes</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Replaces both the dermal and epidermal component</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Includes allograft, xenograft, and tissue-engineered skin </p><p></p><p class="headingAnchor" id="H721478200"><span class="h2">Davison-Kotler classification</span><span class="headingEndMark"> — </span>In a later publication, a potentially universal classification system classifies skin substitutes based upon the following factors  (<a class="graphic graphic_figure graphicRef120664" href="/d/graphic/120664.html" rel="external">figure 1</a>) [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cellularity – Acellular, cellular</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Layering – Single or bilayer</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Replaced region – Epidermis, dermis, or both</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Material used – Natural, synthetic, or both</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Permanence – Temporary (biodegradable), permanent (nonbiodegradable)</p><p></p><p class="headingAnchor" id="H808981106"><span class="h2">Other clinical classifications</span><span class="headingEndMark"> — </span>In addition to the above classification systems, a more clinically inclined system classifies skin substitutes and scaffolds based on material (synthetic, biological, biosynthetic), permanence (temporary or permanent), and location (epidermis, dermis, or both) [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H3596727765"><span class="h1">INDICATIONS FOR USE AND EFFICACY</span><span class="headingEndMark"> — </span>Wound healing is a complex process involving multiple cell types and mediators such as growth factors and cytokines. (See  <a class="medical medical_review" href="/d/html/15080.html" rel="external">"Basic principles of wound healing"</a>.) </p><p>Skin substitutes were initially introduced to manage extensive burns, but their use has extended to include the management of a variety of other acute and chronic wounds such as traumatic wounds, diabetic ulcers, pressure-related skin injuries, venous ulcers, and others [<a href="#rid12">12-15</a>].</p><p>The use of skin substitutes for acute burn wound management and other common chronic wounds is discussed briefly below. The general management of these conditions is discussed in detail in the linked topic reviews.</p><p class="headingAnchor" id="H3552256912"><span class="h2">Burn wounds</span><span class="headingEndMark"> — </span>Skin substitutes improve the long-term functional and cosmetic outcomes in burn patients and increase quality of life [<a href="#rid16">16-21</a>]. During the acute phase of burn treatment, skin substitutes can be used as temporary dressings and are particularly useful for large surface area burns where donor skin availability is limited. In the chronic phase, dermal substitutes are also used to reconstruct and improve burn scars and other defects. (See  <a class="medical medical_review" href="/d/html/114178.html" rel="external">"Treatment of deep burns", section on 'Managing large burn wounds'</a> and  <a class="medical medical_review" href="/d/html/14990.html" rel="external">"Overview of surgical procedures used in the management of burn injuries", section on 'Burn scar revision and timing'</a>.)</p><p>A systematic review identified 20 trials of skin substitutes [<a href="#rid16">16</a>]. For the management of partial-thickness burns, bioengineered skin substitutes and allogeneic cultured skin were at least as effective as topical agents/wound dressings or allograft. In two trials, a bilayered living cell construct (BLCC) had a significantly faster time to healing (11 versus 14 days) compared with autografts, allografts, or xenografts; however, the proportion of patients with ≥75 percent of wound closure was significantly lower. In a separate review, a skin substitute (Biobrane) significantly reduced pain during the treatment of superficial and partial-thickness burn wounds compared with topical agents [<a href="#rid18">18</a>].</p><p>One drawback of skin substitutes in the treatment of burns may be the potential for infection. In a multicenter trial that included 216 burn patients, the rate of invasive infection at sites treated with BLCC was 3 percent (consistent with 1 to 3 percent rate for autografting) and the superficial wound infection rate was 13 percent [<a href="#rid22">22</a>]. In a later systematic review of studies that compared dermal substitutes and split-thickness skin grafts for the treatment of burn wounds, three trials reported either low rates of infection or no significant difference in infection rates between dermal substitutes and skin grafts, and four of the seven trials reported no significant differences in scar quality [<a href="#rid19">19</a>]. Statistical pooling of data was not performed due to heterogeneity of the studies. (See  <a class="medical medical_review" href="/d/html/14985.html" rel="external">"Burn wound infection and sepsis", section on 'Epidemiology and risk factors'</a>.)</p><p class="headingAnchor" id="H2109691460"><span class="h2">Chronic wounds</span><span class="headingEndMark"> — </span>Chronic wounds have derangements of the healing process, including impaired fibroblast replication and keratinocyte migration [<a href="#rid23">23-25</a>]. Skin substitutes can provide cells, growth factors, and other elements that promote reepithelialization and revascularization of the wound. (See  <a class="medical medical_review" href="/d/html/15079.html" rel="external">"Clinical assessment of chronic wounds"</a>.)</p><p class="headingAnchor" id="H2833165234"><span class="h3">Diabetic foot ulcers</span><span class="headingEndMark"> — </span>Among chronic wounds, skin substitutes are most studied for promoting healing of diabetic foot ulcers [<a href="#rid26">26-30</a>]. Wound healing in diabetic ulcers is impaired through of lack of response to growth factors and reduced collagen accumulation [<a href="#rid31">31-33</a>]. (See  <a class="medical medical_review" href="/d/html/8175.html" rel="external">"Management of diabetic foot ulcers", section on 'Local care'</a>.)</p><p>Many types of skin substitutes have been used in the treatment of diabetic foot ulcers, including epidermal, dermal, and bilayer substitutes [<a href="#rid26">26,34-44</a>]. A systematic review identified 17 trials using various skin substitutes (eg, Graftjacket, Hyalograft, Dermagraft, Apligraf, OrCel, Kaloderm) for the treatment of diabetic foot ulcers [<a href="#rid26">26</a>]. Completed closure of diabetic foot ulcers was significantly improved for skin substitutes compared with standard care (risk ratio [RR] 1.55, 95% CI 1.30-1.85). In two trials, there were no significant differences for ulcer recurrence. Among two trials that reported the incidence of lower limb amputations, skin grafts and substitutes were also associated with significantly lower risk for amputation, although the absolute risk reduction for amputation was small. Based upon four trials that directly compared products, no specific type of skin graft or skin substitute was superior to another. </p><p class="headingAnchor" id="H2995594498"><span class="h3">Chronic venous ulcers</span><span class="headingEndMark"> — </span>While the mainstay of treatment of chronic venous ulcers is compression therapy, difficult or large ulcers may require additional measures to achieve wound healing. (See  <a class="medical medical_review" href="/d/html/127144.html" rel="external">"Evaluation and management of chronic venous insufficiency including venous leg ulcer", section on 'Ulcer care'</a>.) </p><p>A variety of skin substitutes have been used in the treatment of chronic venous ulcers [<a href="#rid45">45-52</a>]. In a systematic review, pooled rates of wound healing were significantly improved in two studies using bilayered human skin equivalents compared with standard care (RR 1.51, 95% CI 1.22-1.88) [<a href="#rid48">48</a>]. Allografts (fresh or frozen; five studies) also significantly increased healing compared with standard care (RR 2.0, 95% CI 1.04-3.84). Single-layered dermal skin replacements were not associated with any significant improvements in wound healing.</p><p class="headingAnchor" id="H4150536697"><span class="h3">Pressure-related injury</span><span class="headingEndMark"> — </span>A single trial has evaluated a skin substitute (Oasis wound matrix) for the treatment of pressure-induced skin injury [<a href="#rid53">53</a>]. In this trial, wound healing was significantly improved in 130 adults with stage IV pressure ulcers who received standard care plus the skin substitute compared with standard care alone (proportion with complete wound healing: 40 versus 29 percent; 90 percent reduction in ulcer surface area: 55 versus 38 percent). (See  <a class="medical medical_review" href="/d/html/2887.html" rel="external">"Clinical staging and general management of pressure-induced skin and soft tissue injury"</a>.)</p><p class="headingAnchor" id="H208623463"><span class="h2">Other types of wounds</span><span class="headingEndMark"> — </span>Other studies have demonstrated positive outcomes for a variety of complex wounds [<a href="#rid41">41,54-61</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal wall reconstruction (see  <a class="medical medical_review" href="/d/html/15145.html" rel="external">"Management of the open abdomen in adults"</a> and  <a class="medical medical_review" href="/d/html/96301.html" rel="external">"Management of ventral hernias"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breast reconstruction (see  <a class="medical medical_review" href="/d/html/801.html" rel="external">"Overview of breast reconstruction"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extremity reconstruction (see  <a class="medical medical_review" href="/d/html/16527.html" rel="external">"Surgical reconstruction of the upper extremity"</a> and  <a class="medical medical_review" href="/d/html/15121.html" rel="external">"Surgical reconstruction of the lower extremity"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epidermolysis bullosa (see  <a class="medical medical_review" href="/d/html/15453.html" rel="external">"Overview of the management of epidermolysis bullosa", section on 'Skin and wound care'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pyoderma gangrenosum (PG) (see  <a class="medical medical_review" href="/d/html/83623.html" rel="external">"Pyoderma gangrenosum: Treatment and prognosis", section on 'Wound management'</a>)</p><p></p><p class="headingAnchor" id="H2091737136"><span class="h2">Cost considerations</span><span class="headingEndMark"> — </span>In the era of increasing health care costs associated with new technologies, several cost analysis studies suggest that despite the high initial costs, skin substitutes can shorten time to wound closure and result in an overall cost reduction [<a href="#rid62">62,63</a>]. </p><p class="headingAnchor" id="H1750927502"><span class="h1">GENERAL PROPERTIES AND APPLICATION</span><span class="headingEndMark"> — </span>The successful use of skin substitutes is ultimately predicated on the basic principles of wound management. (See  <a class="medical medical_review" href="/d/html/99040.html" rel="external">"Overview of treatment of chronic wounds", section on 'Wound bed preparation'</a> and  <a class="medical medical_review" href="/d/html/114178.html" rel="external">"Treatment of deep burns", section on 'Early burn excision'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>The underlying causes of poor wound healing must be addressed. Underlying patient comorbidities need to be addressed to optimize the wound healing environment. As with skin grafting, impaired perfusion needs to be corrected before using skin substitutes. (See  <a class="medical medical_review" href="/d/html/112216.html" rel="external">"Risk factors for impaired wound healing and wound complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior to placement of a skin substitute, the wound bed should be debrided of all necrotic tissue so that the wound margins contain only healthy cells. Skin substitutes do not replace an inadequately debrided wound bed. (See  <a class="medical medical_review" href="/d/html/15912.html" rel="external">"Basic principles of wound management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The recipient wound bed must be free of infection. Skin substitutes are not effective in infected wounds that have not been adequately treated.</p><p></p><p>It is essential to have full understanding of the material being used and its indications. (See <a class="local">'Terminology and classification'</a> above and <a class="local">'Indications for use and efficacy'</a> above.)</p><p class="headingAnchor" id="H4272552651"><span class="h2">Dehydrated human amniotic/chorion membrane</span><span class="headingEndMark"> — </span>Naturally occurring membrane materials, such as human amniotic membrane, have been successfully used for treating partial-thickness or full-thickness wounds [<a href="#rid64">64-67</a>]. </p><p>Sterilized, dehydrated human amnion/chorion membrane (DHACM) is composed of a single layer of epithelial cells, a basement membrane, and an avascular connective tissue matrix. DHACM contains growth factors that promote wound healing, including platelet-derived growth factor A and B, basic fibroblastic growth factor, and transforming growth factor beta 1 [<a href="#rid68">68,69</a>]. DHACM is stable at ambient temperatures for up to five years. </p><p>DHACM has been used for managing burn wounds, diabetic foot ulcers, venous leg ulcers, pressure ulcers, surgical wounds, and traumatic wounds. </p><p>DHACM should be prepared using aseptic technique before applying to a clean wound bed that has been debrided as necessary. DHACM can be applied to a wet or dry wound bed. Any number of methods can be used to secure DHACM to the wound, followed by the appropriate wound dressing. DHACM can be changed weekly or biweekly depending on the needs of the patient [<a href="#rid70">70</a>]. </p><p class="headingAnchor" id="H2823693905"><span class="h2">Dermal replacement template</span><span class="headingEndMark"> — </span>Dermal replacement template (DRT) is composed of a cross-linked bovine collagen and glycosaminoglycan dermal layer and a silicone epidermal layer. </p><p>DRT (eg, Matriderm, Integra dermal regeneration template [IDRT]) can be used for partial-thickness or full-thickness wounds, including burn wounds, pressure ulcers, venous leg ulcers, diabetic foot ulcers, and other surgical wounds [<a href="#rid36">36,41</a>]. A commonly used DRT is Matriderm. This product is available outside the United States and is widely used in Western European countries such as the United Kingdom, Germany, and Spain, among others. Matriderm is a highly porous dermal scaffold comprised of bovine collagen (collagen type I, III, and V) cross-linked to an elastin hydrolysate. The matrices (1 or 2 mm thick sheets) are irradiated (approximately 1000 Gy) and the product is stored at room temperature. Matriderm can be used as a one-stage procedure with a split-thickness skin graft, and its use may minimize loss in pliability and elasticity of the skin [<a href="#rid71">71</a>]. </p><p>The application of DRT is a straightforward process. The DRT product is cut to the size of the wound and placed in the wound bed. One option is to moisten the DRT with normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> prior to applying it to the wound. Another option that seems useful is to apply the dry template to the wound, then wet it with saline. This reduces difficulty in handling the material. After ensuring there are no air bubbles beneath the DRT, the edges are then secured to the wound edges. (See  <a class="medical medical_review" href="/d/html/15118.html" rel="external">"Skin autografting", section on 'Graft placement and fixation'</a>.)</p><p>Appropriate dressings are used to secure it in place and protect the wound area. The outer dressing can be changed as needed depending on the volume of exudate. Once the template has become vascularized (usually by 14 days), any silicone layer can be removed and an autograft applied [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/d/html/15118.html" rel="external">"Skin autografting", section on 'Recipient site dressings and care'</a>.)</p><p>In one trial, the combination of DRT and postoperative negative-pressure therapy compared with DRT alone significantly increased the take rate (98 versus 78 percent) [<a href="#rid41">41</a>]. The interval between DRT and subsequent autografting also decreased from 24 to 10 days. (See  <a class="medical medical_review" href="/d/html/15118.html" rel="external">"Skin autografting", section on 'Graft immobilization'</a> and  <a class="medical medical_review" href="/d/html/2881.html" rel="external">"Negative pressure wound therapy"</a>.)</p><p class="headingAnchor" id="H1106466619"><span class="h2">Acellular dermal matrix</span><span class="headingEndMark"> — </span>Acellular dermal matrix (ADM) is an allograft (also called homograft) product created from skin from a nongenetically identical deceased human donor that has been processed to remove the epidermis using a sequential decellularization process [<a href="#rid73">73,74</a>]. ADM (eg, Alloderm) can be distributed fresh or cryopreserved after glycerol preservation from cadavers. These decellularized matrices fully integrate into the wound bed after application, replacing lost dermal tissue and providing a scaffold into which the recipient's cells can grow and become vascularized, ultimately regenerating into normal skin. </p><p>ADMs are used in the reconstruction of skin defects, including burn wounds and abdominal wall defects, as well as for breast reconstruction. The application of ADM over superficial partial-thickness wounds can minimize pain and facilitate reepithelialization. </p><p>Before application, preserved ADM must be rehydrated in warm sterile <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> solution. It should be applied within four hours of rehydration with the dermal side down and the basement membrane side facing up. </p><p>Following placement and fixation, we dress the ADM in three layers. We use an inner layer of petrolatum-based antimicrobial impregnated gauze, a middle layer of damp <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> gauze, and an outer layer of a dry gauze covered by an elastic bandage. The inner layer is not changed for the first seven days, but the outer two layers can be changed as often as necessary [<a href="#rid75">75</a>]. </p><p class="headingAnchor" id="H4138577871"><span class="h2">Synthetic dermal substitutes</span><span class="headingEndMark"> — </span>In contrast to ADM or IDRT, Biodegradable Temporizing Matrix (BTM) is a fully synthetic product. It consists of a 2-mm thin biodegradable polyurethane bonded to a nonbiodegradable polyurethane sealing membrane which is 150 mm thick. Like IDRT, it is applied in a two-stage approach. In an animal model, BTM had a more extensive vascular network and a greater inflammatory response compared with IDRT [<a href="#rid76">76</a>]. In a study of 30 patients, the authors described the potential advantage of the polyurethane origin of BTM against metalloproteinases from bacterial and lysosomal enzymes, which otherwise degrade collagen in collagen-based matrices [<a href="#rid77">77</a>]. No randomized trials have demonstrated superiority of BTM over other dermal substitutes [<a href="#rid76">76-78</a>]. Given the potential protective nature of BTM against infectious complications and its ability to remain in place for longer periods without the need for delamination and application of split-thickness skin graft, BTM might prove to be beneficial in coverage of wound in those with extensively large percentage total body surface area burns.</p><p class="headingAnchor" id="H1531755050"><span class="h2">Bilayered living cellular construct</span><span class="headingEndMark"> — </span>The bilayered living cellular construct (BLCC) has two components: </p><p class="bulletIndent1"><span class="glyph">●</span>Dermal part – Bovine type I collagen with human neonatal foreskin fibroblasts</p><p class="bulletIndent1"><span class="glyph">●</span>Epidermal part – Keratinocytes</p><p></p><p>BLCC (eg, IDRT, Apligraf) can be used to treat burn wounds, venous leg ulcers, diabetic foot ulcers, pyoderma granulosum, acute wounds, epidermolysis bullosa, and post-radiation ulcers. In the author's practice, BLCC is more often in the acute burn setting, but its use has been gradually extended to become a versatile additional tool for burn reconstruction. </p><p>A commonly used BLCC is IDRT [<a href="#rid79">79</a>]. The BLCC template serves as a scaffold for neovascular and cellular infiltration from the wound bed. It can be used as a standard two-stage dermal template or as a single stage. In the two-stage procedure, the BLCC scaffold is gradually replaced with the patient's own collagen, forming a neo-dermis. After two to three weeks, the silicone epidermal layer is removed and the wound is covered with a thin split-thickness skin graft. </p><p>BLCC should be handled with aseptic technique and applied directly to a clean wound base after proper debridement and hemostasis. As with autografts, BLCC can be meshed or slit before application to allow for drainage of exudate. The product can be secured in place using any one of a variety of techniques. (See  <a class="medical medical_review" href="/d/html/15118.html" rel="external">"Skin autografting", section on 'Graft meshing'</a> and  <a class="medical medical_review" href="/d/html/15118.html" rel="external">"Skin autografting", section on 'Graft placement and fixation'</a>.)</p><p>A nonadherent dressing should be placed over the BLCC followed by the appropriate wound dressing. (See  <a class="medical medical_review" href="/d/html/15118.html" rel="external">"Skin autografting", section on 'Recipient site dressings and care'</a>.)</p><p>The wound should be evaluated and dressings changed at least once per week. Reapplication may be necessary. Outer dressings can be changed more frequently, as needed [<a href="#rid80">80</a>]. Evidence of neovascularization occurs in a minimum of 10 days but usually within two to three weeks. When this has occurred, any silicone layer can be removed and a split-thickness skin graft applied.</p><p class="headingAnchor" id="H3766487830"><span class="h2">Xenografts</span><span class="headingEndMark"> — </span>Skin xenografts (heterografts) are obtained from an unrelated species and can be used as temporary skin coverage, particularly for large burn wounds. Porcine grafts have been the most commonly used xenograft [<a href="#rid81">81,82</a>], however, there’s been research into the use of tilapia fish skin as xenograft [<a href="#rid83">83-85</a>]. Xenografts are generally readily available but may not be as effective as allografts and are not generally used in resource-rich environments; however, xenografts do have an ongoing role in resource-limited countries where access to allograft and advanced technologies is limited or nonexistent. Xenografts are handled and applied in a manner similar to autografts. (See  <a class="medical medical_review" href="/d/html/15118.html" rel="external">"Skin autografting"</a>.)</p><p class="headingAnchor" id="H2827533305"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117599.html" rel="external">"Society guideline links: Chronic wound management"</a>.)</p><p class="headingAnchor" id="H694579027"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin substitutes</strong> – Skin substitutes are a heterogeneous group of biologic, synthetic, or biosynthetic materials that can provide temporary or permanent coverage of open skin wounds. The aim of skin substitutes is to replicate the properties of the normal skin. Skin substitutes are an important adjunct in the management of acute or chronic wounds. (See <a class="local">'Introduction'</a> above and <a class="local">'Available products'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – There is no universally accepted classification system that allows for simple categorization of all the products that are commercially available  (<a class="graphic graphic_table graphicRef118082" href="/d/graphic/118082.html" rel="external">table 2</a> and <a class="graphic graphic_figure graphicRef120664" href="/d/graphic/120664.html" rel="external">figure 1</a>). Skin substitutes can be classified based on clinical features, including replaced skin component (epidermis, dermis, or both) or required permanence (temporary, permanent), or by composition, including material used (biologic, synthetic, or both), layering (single layer, bilayer), and cellularity (acellular, cellular). (See <a class="local">'Terminology and classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Skin substitutes can be used to cover acute burn wounds or other injuries, or for burn wound reconstruction, such as for release of extensive severe post-burn contractures, or other forms of reconstruction, such as for abdominal wall or breast reconstruction. (See <a class="local">'Indications for use and efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General properties and application</strong> – Each skin substitute has unique advantages and disadvantages  (<a class="graphic graphic_table graphicRef118083" href="/d/graphic/118083.html" rel="external">table 1</a>). The type of skin substitute chosen depends upon the type of wound (ie, acute, chronic), its etiology (eg, trauma, chronic inflammation), the skin component that requires replacement (ie, epidermis, dermis, or both), and need for permanence. In addition, the desired functional and aesthetic outcomes need to be considered. Commonly used skin substitutes, their usage, and efficacy are reviewed above. (See <a class="local">'General properties and application'</a> above.)  </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Figus A, Leon-Villapalos J, Philp B, Dziewulski P. Severe multiple extensive postburn contractures: a simultaneous approach with total scar tissue excision and resurfacing with dermal regeneration template. J Burn Care Res 2007; 28:913.</a></li><li><a class="nounderline abstract_t">Buchanan PJ, Kung TA, Cederna PS. Evidence-Based Medicine: Wound Closure. Plast Reconstr Surg 2016; 138:257S.</a></li><li><a class="nounderline abstract_t">Nyame TT, Chiang HA, Orgill DP. Clinical applications of skin substitutes. Surg Clin North Am 2014; 94:839.</a></li><li><a class="nounderline abstract_t">Tenenhaus M, Rennekampff HO. Current Concepts in Tissue Engineering: Skin and Wound. Plast Reconstr Surg 2016; 138:42S.</a></li><li><a class="nounderline abstract_t">Chua AW, Khoo YC, Tan BK, et al. Skin tissue engineering advances in severe burns: review and therapeutic applications. Burns Trauma 2016; 4:3.</a></li><li><a class="nounderline abstract_t">van der Veen VC, van der Wal MB, van Leeuwen MC, et al. Biological background of dermal substitutes. Burns 2010; 36:305.</a></li><li><a class="nounderline abstract_t">Hughes OB, Rakosi A, Macquhae F, et al. A Review of Cellular and Acellular Matrix Products: Indications, Techniques, and Outcomes. Plast Reconstr Surg 2016; 138:138S.</a></li><li class="breakAll">Evidence-based Practice Center Technical Brief Protocol. Project Title: Skin Substitutes for Treating Chronic Wounds https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/skin-substitute_0.pdf (Accessed on August 02, 2023).</li><li><a class="nounderline abstract_t">Kumar P. Classification of skin substitutes. Burns 2008; 34:148.</a></li><li><a class="nounderline abstract_t">Davison-Kotler E, Sharma V, Kang NV, García-Gareta E. A Universal Classification System of Skin Substitutes Inspired by Factorial Design. Tissue Eng Part B Rev 2018; 24:279.</a></li><li><a class="nounderline abstract_t">Ferreira M, Paggiaro A, Isaac C, et al.. Skin substitutes: Current concepts and a new classification system. Rev Bras Cir Plast 2011; 26:696.</a></li><li><a class="nounderline abstract_t">Palackic A, Duggan RP, Campbell MS, et al. The Role of Skin Substitutes in Acute Burn and Reconstructive Burn Surgery: An Updated Comprehensive Review. Semin Plast Surg 2022; 36:33.</a></li><li><a class="nounderline abstract_t">Han G, Ceilley R. Chronic Wound Healing: A Review of Current Management and Treatments. Adv Ther 2017; 34:599.</a></li><li><a class="nounderline abstract_t">Nicholas MN, Yeung J. Current Status and Future of Skin Substitutes for Chronic Wound Healing. J Cutan Med Surg 2017; 21:23.</a></li><li class="breakAll">Skin Substitutes for Treating Chronic Wounds, Agency for Healthcare Research and Quality (US).</li><li><a class="nounderline abstract_t">Pham C, Greenwood J, Cleland H, et al. Bioengineered skin substitutes for the management of burns: a systematic review. Burns 2007; 33:946.</a></li><li><a class="nounderline abstract_t">Shahrokhi S, Arno A, Jeschke MG. The use of dermal substitutes in burn surgery: acute phase. Wound Repair Regen 2014; 22:14.</a></li><li><a class="nounderline abstract_t">Wasiak J, Cleland H, Campbell F, Spinks A. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev 2013; :CD002106.</a></li><li><a class="nounderline abstract_t">Widjaja W, Tan J, Maitz PKM. Efficacy of dermal substitute on deep dermal to full thickness burn injury: a systematic review. ANZ J Surg 2017; 87:446.</a></li><li><a class="nounderline abstract_t">Hoogewerf CJ, Van Baar ME, Hop MJ, et al. Topical treatment for facial burns. Cochrane Database Syst Rev 2013; :CD008058.</a></li><li><a class="nounderline abstract_t">Yeong EK, Chen SH, Tang YB. The treatment of bone exposure in burns by using artificial dermis. Ann Plast Surg 2012; 69:607.</a></li><li><a class="nounderline abstract_t">Heimbach DM, Warden GD, Luterman A, et al. Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. J Burn Care Rehabil 2003; 24:42.</a></li><li><a class="nounderline abstract_t">Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341:738.</a></li><li><a class="nounderline abstract_t">Telgenhoff D, Shroot B. Cellular senescence mechanisms in chronic wound healing. Cell Death Differ 2005; 12:695.</a></li><li><a class="nounderline abstract_t">Agren MS, Steenfos HH, Dabelsteen S, et al. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. J Invest Dermatol 1999; 112:463.</a></li><li><a class="nounderline abstract_t">Santema TB, Poyck PP, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev 2016; 2:CD011255.</a></li><li><a class="nounderline abstract_t">Paggiaro AO, Menezes AG, Ferrassi AD, et al. Biological effects of amniotic membrane on diabetic foot wounds: a systematic review. J Wound Care 2018; 27:S19.</a></li><li><a class="nounderline abstract_t">Guo X, Mu D, Gao F. Efficacy and safety of acellular dermal matrix in diabetic foot ulcer treatment: A systematic review and meta-analysis. Int J Surg 2017; 40:1.</a></li><li><a class="nounderline abstract_t">Haugh AM, Witt JG, Hauch A, et al. Amnion Membrane in Diabetic Foot Wounds: A Meta-analysis. Plast Reconstr Surg Glob Open 2017; 5:e1302.</a></li><li><a class="nounderline abstract_t">Gordon AJ, Alfonso AR, Nicholson J, Chiu ES. Evidence for Healing Diabetic Foot Ulcers With Biologic Skin Substitutes: A Systematic Review and Meta-Analysis. Ann Plast Surg 2019; 83:S31.</a></li><li><a class="nounderline abstract_t">Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366:1736.</a></li><li><a class="nounderline abstract_t">Loot MA, Kenter SB, Au FL, et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol 2002; 81:153.</a></li><li><a class="nounderline abstract_t">Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest 2007; 117:1219.</a></li><li><a class="nounderline abstract_t">Climov M, Bayer LR, Moscoso AV, et al. The Role of Dermal Matrices in Treating Inflammatory and Diabetic Wounds. Plast Reconstr Surg 2016; 138:148S.</a></li><li><a class="nounderline abstract_t">Reyzelman A, Crews RT, Moore JC, et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int Wound J 2009; 6:196.</a></li><li><a class="nounderline abstract_t">Driver VR, Lavery LA, Reyzelman AM, et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. Wound Repair Regen 2015; 23:891.</a></li><li><a class="nounderline abstract_t">Tchero H, Herlin C, Bekara F, et al. Failure rates of artificial dermis products in treatment of diabetic foot ulcer: A systematic review and network meta-analysis. Wound Repair Regen 2017; 25:691.</a></li><li><a class="nounderline abstract_t">Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24:290.</a></li><li><a class="nounderline abstract_t">Kirsner RS, Sabolinski ML, Parsons NB, et al. Comparative effectiveness of a bioengineered living cellular construct vs. a dehydrated human amniotic membrane allograft for the treatment of diabetic foot ulcers in a real world setting. Wound Repair Regen 2015; 23:737.</a></li><li><a class="nounderline abstract_t">Zelen CM, Serena TE, Gould L, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J 2016; 13:272.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Rose C, Angele P, et al. Development of new reconstructive techniques: use of Integra in combination with fibrin glue and negative-pressure therapy for reconstruction of acute and chronic wounds. Plast Reconstr Surg 2004; 113:525.</a></li><li><a class="nounderline abstract_t">Brem H, Balledux J, Bloom T, et al. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg 2000; 135:627.</a></li><li><a class="nounderline abstract_t">Edmonds M, European and Australian Apligraf Diabetic Foot Ulcer Study Group. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds 2009; 8:11.</a></li><li><a class="nounderline abstract_t">Martinson M, Martinson N. A comparative analysis of skin substitutes used in the management of diabetic foot ulcers. J Wound Care 2016; 25:S8.</a></li><li><a class="nounderline abstract_t">Serena TE, Carter MJ, Le LT, et al. A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Wound Repair Regen 2014; 22:688.</a></li><li><a class="nounderline abstract_t">Gould LJ, Dosi G, Couch K, et al. Modalities to Treat Venous Ulcers: Compression, Surgery, and Bioengineered Tissue. Plast Reconstr Surg 2016; 138:199S.</a></li><li><a class="nounderline abstract_t">Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol 1998; 134:293.</a></li><li><a class="nounderline abstract_t">Jones JE, Nelson EA, Al-Hity A. Skin grafting for venous leg ulcers. Cochrane Database Syst Rev 2013; :CD001737.</a></li><li><a class="nounderline abstract_t">Towler MA, Rush EW, Richardson MK, Williams CL. Randomized, Prospective, Blinded-Enrollment, Head-To-Head Venous Leg Ulcer Healing Trial Comparing Living, Bioengineered Skin Graft Substitute (Apligraf) with Living, Cryopreserved, Human Skin Allograft (TheraSkin). Clin Podiatr Med Surg 2018; 35:357.</a></li><li><a class="nounderline abstract_t">Harding K, Sumner M, Cardinal M. A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. Int Wound J 2013; 10:132.</a></li><li><a class="nounderline abstract_t">Bianchi C, Cazzell S, Vayser D, et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix® ) allograft for the treatment of venous leg ulcers. Int Wound J 2018; 15:114.</a></li><li><a class="nounderline abstract_t">Alvarez OM, Makowitz L, Patel M. Venous Ulcers Treated With a Hyaluronic Acid Extracellular Matrix and Compression Therapy: Interim Analysis of a Randomized Controlled Trial. Wounds 2017; 29:E51.</a></li><li><a class="nounderline abstract_t">Brown-Etris M, Milne CT, Hodde JP. An extracellular matrix graft (Oasis® wound matrix) for treating full-thickness pressure ulcers: A randomized clinical trial. J Tissue Viability 2019; 28:21.</a></li><li><a class="nounderline abstract_t">Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J 2006; 3:181.</a></li><li><a class="nounderline abstract_t">Rehim SA, Singhal M, Chung KC. Dermal skin substitutes for upper limb reconstruction: current status, indications, and contraindications. Hand Clin 2014; 30:239.</a></li><li><a class="nounderline abstract_t">Ryssel H, Germann G, Kloeters O, et al. Dermal substitution with Matriderm(®) in burns on the dorsum of the hand. Burns 2010; 36:1248.</a></li><li><a class="nounderline abstract_t">Dantzer E, Braye FM. Reconstructive surgery using an artificial dermis (Integra): results with 39 grafts. Br J Plast Surg 2001; 54:659.</a></li><li><a class="nounderline abstract_t">Groos N, Guillot M, Zilliox R, Braye FM. Use of an artificial dermis (Integra) for the reconstruction of extensive burn scars in children. About 22 grafts. Eur J Pediatr Surg 2005; 15:187.</a></li><li><a class="nounderline abstract_t">Iorio ML, Shuck J, Attinger CE. Wound healing in the upper and lower extremities: a systematic review on the use of acellular dermal matrices. Plast Reconstr Surg 2012; 130:232S.</a></li><li><a class="nounderline abstract_t">Ellis CV, Kulber DA. Acellular dermal matrices in hand reconstruction. Plast Reconstr Surg 2012; 130:256S.</a></li><li><a class="nounderline abstract_t">Ho G, Nguyen TJ, Shahabi A, et al. A systematic review and meta-analysis of complications associated with acellular dermal matrix-assisted breast reconstruction. Ann Plast Surg 2012; 68:346.</a></li><li><a class="nounderline abstract_t">Schonfeld WH, Villa KF, Fastenau JM, et al. An economic assessment of Apligraf (Graftskin) for the treatment of hard-to-heal venous leg ulcers. Wound Repair Regen 2000; 8:251.</a></li><li><a class="nounderline abstract_t">Redekop WK, McDonnell J, Verboom P, et al. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics 2003; 21:1171.</a></li><li><a class="nounderline abstract_t">Yang C, Xiong AB, He XC, et al. Efficacy and feasibility of amniotic membrane for the treatment of burn wounds: A meta-analysis. J Trauma Acute Care Surg 2021; 90:744.</a></li><li><a class="nounderline abstract_t">Kesting MR, Wolff KD, Hohlweg-Majert B, Steinstraesser L. The role of allogenic amniotic membrane in burn treatment. J Burn Care Res 2008; 29:907.</a></li><li><a class="nounderline abstract_t">Ramakrishnan KM, Jayaraman V. Management of partial-thickness burn wounds by amniotic membrane: a cost-effective treatment in developing countries. Burns 1997; 23 Suppl 1:S33.</a></li><li><a class="nounderline abstract_t">Fairbairn NG, Randolph MA, Redmond RW. The clinical applications of human amnion in plastic surgery. J Plast Reconstr Aesthet Surg 2014; 67:662.</a></li><li><a class="nounderline abstract_t">Fetterolf DE, Snyder RJ. Scientific and clinical support for the use of dehydrated amniotic membrane in wound management. Wounds 2012; 24:299.</a></li><li><a class="nounderline abstract_t">Koob TJ, Rennert R, Zabek N, et al. Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J 2013; 10:493.</a></li><li><a class="nounderline abstract_t">Hu S, Kirsner RS, Falanga V, et al. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study. Wound Repair Regen 2006; 14:427.</a></li><li><a class="nounderline abstract_t">Ryssel H, Gazyakan E, Germann G, Ohlbauer M. The use of MatriDerm in early excision and simultaneous autologous skin grafting in burns--a pilot study. Burns 2008; 34:93.</a></li><li class="breakAll">https://www.integralife.com/integra-dermal-regeneration-template/product/wound-reconstruction-care-inpatient-acute-or-integra-dermal-regeneration-template (Accessed on June 07, 2018).</li><li><a class="nounderline abstract_t">Hogg P, Rooney P, Ingham E, Kearney JN. Development of a decellularised dermis. Cell Tissue Bank 2013; 14:465.</a></li><li><a class="nounderline abstract_t">Wai RT. Use of glycerol-preserved skin in plastic surgery. Burns 1994; 20 Suppl 1:S27.</a></li><li class="breakAll">https://allergan-web-cdn-prod.azureedge.net/actavis/actavis/media/allergan-pdf-documents/labeling/alloderm/adm_ifu_121p0541f_t3.pdf (Accessed on June 07, 2018).</li><li><a class="nounderline abstract_t">Cheshire PA, Herson MR, Cleland H, Akbarzadeh S. Artificial dermal templates: A comparative study of NovoSorb™ Biodegradable Temporising Matrix (BTM) and Integra(®) Dermal Regeneration Template (DRT). Burns 2016; 42:1088.</a></li><li><a class="nounderline abstract_t">Lo CH, Brown JN, Dantzer EJG, et al. Wound healing and dermal regeneration in severe burn patients treated with NovoSorb® Biodegradable Temporising Matrix: A prospective clinical study. Burns 2022; 48:529.</a></li><li><a class="nounderline abstract_t">Greenwood JE, Schmitt BJ, Wagstaff MJ. Experience with a synthetic bilayer Biodegradable Temporising Matrix in significant burn injury. Burns Open 2018; 2:17.</a></li><li><a class="nounderline abstract_t">Jeng JC, Fidler PE, Sokolich JC, et al. Seven years' experience with Integra as a reconstructive tool. J Burn Care Res 2007; 28:120.</a></li><li class="breakAll">https://mimedx.com/epifix/ (Accessed on June 07, 2018).</li><li><a class="nounderline abstract_t">Song IC, Bromberg BE, Mohn MP, Koehnlein E. Heterografts as biological dressings for large skin wounds. Surgery 1966; 59:576.</a></li><li><a class="nounderline abstract_t">Elliott RA Jr, Hoehn JG. Use of commercial porcine skin for wound dressings. Plast Reconstr Surg 1973; 52:401.</a></li><li><a class="nounderline abstract_t">Lima Júnior EM, De Moraes Filho MO, Costa BA, et al. Innovative Burn Treatment Using Tilapia Skin as a Xenograft: A Phase II Randomized Controlled Trial. J Burn Care Res 2020; 41:585.</a></li><li><a class="nounderline abstract_t">Lima Júnior EM, de Moraes Filho MO, Costa BA, et al. Nile Tilapia Fish Skin-Based Wound Dressing Improves Pain and Treatment-Related Costs of Superficial Partial-Thickness Burns: A Phase III Randomized Controlled Trial. Plast Reconstr Surg 2021; 147:1189.</a></li><li><a class="nounderline abstract_t">Luze H, Nischwitz SP, Smolle C, et al. The Use of Acellular Fish Skin Grafts in Burn Wound Management-A Systematic Review. Medicina (Kaunas) 2022; 58.</a></li></ol></div><div id="topicVersionRevision">Topic 118064 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17925635" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Severe multiple extensive postburn contractures: a simultaneous approach with total scar tissue excision and resurfacing with dermal regeneration template.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27556770" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evidence-Based Medicine: Wound Closure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25085091" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical applications of skin substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27556774" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Current Concepts in Tissue Engineering: Skin and Wound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27574673" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Skin tissue engineering advances in severe burns: review and therapeutic applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19897310" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Biological background of dermal substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27556754" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A Review of Cellular and Acellular Matrix Products: Indications, Techniques, and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27556754" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A Review of Cellular and Acellular Matrix Products: Indications, Techniques, and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17869426" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Classification of skin substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29336231" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A Universal Classification System of Skin Substitutes Inspired by Factorial Design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Skin substitutes: Current concepts and a new classification system</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35706557" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Role of Skin Substitutes in Acute Burn and Reconstructive Burn Surgery: An Updated Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28108895" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chronic Wound Healing: A Review of Current Management and Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27530398" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Current Status and Future of Skin Substitutes for Chronic Wound Healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27530398" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Current Status and Future of Skin Substitutes for Chronic Wound Healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17825993" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bioengineered skin substitutes for the management of burns: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24393152" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The use of dermal substitutes in burn surgery: acute phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543513" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dressings for superficial and partial thickness burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28304144" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy of dermal substitute on deep dermal to full thickness burn injury: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440823" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Topical treatment for facial burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23154329" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The treatment of bone exposure in burns by using artificial dermis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12543990" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10471461" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cutaneous wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15861190" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cellular senescence mechanisms in chronic wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10201530" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26866804" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Skin grafting and tissue replacement for treating foot ulcers in people with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29419367" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Biological effects of amniotic membrane on diabetic foot wounds: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28232031" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of acellular dermal matrix in diabetic foot ulcer treatment: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28507863" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Amnion Membrane in Diabetic Foot Wounds: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31513064" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evidence for Healing Diabetic Foot Ulcers With Biologic Skin Substitutes: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291068" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Wound healing and its impairment in the diabetic foot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11998867" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17476353" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cellular and molecular basis of wound healing in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27556755" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The Role of Dermal Matrices in Treating Inflammatory and Diabetic Wounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19368581" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26297933" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A clinical trial of Integra Template for diabetic foot ulcer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28597935" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Failure rates of artificial dermis products in treatment of diabetic foot ulcer: A systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213881" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26100572" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparative effectiveness of a bioengineered living cellular construct vs. a dehydrated human amniotic membrane allograft for the treatment of diabetic foot ulcers in a real world setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26695998" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14758212" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Development of new reconstructive techniques: use of Integra in combination with fibrin glue and negative-pressure therapy for reconstruction of acute and chronic wounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10843357" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19189997" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Apligraf in the treatment of neuropathic diabetic foot ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27681811" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A comparative analysis of skin substitutes used in the management of diabetic foot ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25224019" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27556762" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Modalities to Treat Venous Ulcers: Compression, Surgery, and Bioengineered Tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521027" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440784" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Skin grafting for venous leg ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29861018" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Randomized, Prospective, Blinded-Enrollment, Head-To-Head Venous Leg Ulcer Healing Trial Comparing Living, Bioengineered Skin Graft Substitute (Apligraf) with Living, Cryopreserved, Human Skin Allograft (TheraSkin).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23506344" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29024419" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix®) allograft for the treatment of venous leg ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28759431" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Venous Ulcers Treated With a Hyaluronic Acid Extracellular Matrix and Compression Therapy: Interim Analysis of a Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30509850" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : An extracellular matrix graft (Oasis®wound matrix) for treating full-thickness pressure ulcers: A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16984575" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24731613" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Dermal skin substitutes for upper limb reconstruction: current status, indications, and contraindications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20554395" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dermal substitution with Matriderm(®) in burns on the dorsum of the hand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11728107" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Reconstructive surgery using an artificial dermis (Integra): results with 39 grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15999312" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Use of an artificial dermis (Integra) for the reconstruction of extensive burn scars in children. About 22 grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23096978" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Wound healing in the upper and lower extremities: a systematic review on the use of acellular dermal matrices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23096981" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Acellular dermal matrices in hand reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22421476" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A systematic review and meta-analysis of complications associated with acellular dermal matrix-assisted breast reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11013015" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : An economic assessment of Apligraf (Graftskin) for the treatment of hard-to-heal venous leg ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14594438" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The cost effectiveness of Apligraf treatment of diabetic foot ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33284236" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy and feasibility of amniotic membrane for the treatment of burn wounds: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18849850" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The role of allogenic amniotic membrane in burn treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9177900" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Management of partial-thickness burn wounds by amniotic membrane: a cost-effective treatment in developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24560801" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The clinical applications of human amnion in plastic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25876055" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Scientific and clinical support for the use of dehydrated amniotic membrane in wound management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23902526" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16939570" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17644263" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The use of MatriDerm in early excision and simultaneous autologous skin grafting in burns--a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17644263" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The use of MatriDerm in early excision and simultaneous autologous skin grafting in burns--a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22875198" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Development of a decellularised dermis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8198738" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Use of glycerol-preserved skin in plastic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8198738" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Use of glycerol-preserved skin in plastic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27222383" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Artificial dermal templates: A comparative study of NovoSorb™Biodegradable Temporising Matrix (BTM) and Integra(®) Dermal Regeneration Template (DRT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34407914" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Wound healing and dermal regeneration in severe burn patients treated with NovoSorb®Biodegradable Temporising Matrix: A prospective clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Experience with a synthetic bilayer Biodegradable Temporising Matrix in significant burn injury</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17211211" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Seven years' experience with Integra as a reconstructive tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17211211" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Seven years' experience with Integra as a reconstructive tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5326469" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Heterografts as biological dressings for large skin wounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4582528" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Use of commercial porcine skin for wound dressings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31900475" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Innovative Burn Treatment Using Tilapia Skin as a Xenograft: A Phase II Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33890902" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Nile Tilapia Fish Skin-Based Wound Dressing Improves Pain and Treatment-Related Costs of Superficial Partial-Thickness Burns: A Phase III Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35888631" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The Use of Acellular Fish Skin Grafts in Burn Wound Management-A Systematic Review.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
